CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 109 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04435769
NCT04435769N/ACompleted

Non-interventional Study Describing Direct Costs Related to Anticoagulation Treatment in Patients With Nonvalvular Atrial Fibrillation (NVAF) in Secondary Stroke Prevention Prescribed Apixaban or Warfarin Treatment

Pfizer·observational·Posted Jun 17, 2020·Updated Feb 8, 2023

In Brief

An observational study for Atrial Fibrillation. Completed, enrolled 109 participants across 1 site.

Detailed Summary

To describe the direct costs related to warfarin/apixaban treatment

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCzechia
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 17, 2020
Enrollment StartAug 4, 2020
Primary CompletionMay 31, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.0 years ago